STUDY PARTICIPANTS
Who could take part?
To take part in the study, patients had to meet the following requirements:
0
Male or female, 18 years Confirmed diagnosis Hemolysis confirmed by
of age or older. of PNH with 1 or more a blood test.
related sign or symptom.
Any patient who had ever had eculizumab treatment or who was unwell due to a fever or infection
could not take part.
All patients needed to have had a meningococcal vaccination no more than 3 years before taking
part. If they had previously had a meningococcal infection, they could not take part.
How many patients took part?
134 112 246
men women patients
Patients were aged between 18 and 86 years.
Where was the study done?
The study took place in 123 study centers in 25 countries across North America, South America,
Europe, Asia, Africa, and Australia. The majority of patients (50%) were from Asia.
ATEXI Protocol, ALXN1210-PNH-301 SPONSOR CONTACT INFORMATION
LEXION Europe, 2016-002025-11 1-888-765-4747
Â© CertarUaSA , Inc. 2020. Al rights reserved United States, NCT02946463 medinfo@alexion.com 5